|

Rapcabtagene autoleucel Clinical Trials

3 actively recruiting trials across 2 locations

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Novartis Pharmaceuticals3

Indications

  • Scleroderma, Diffuse1
  • Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)1
  • Lupus Nephritis1
  • Lupus Erythematosus, Systemic1
  • Lupus1

Other1 trial

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Phase 1/2

Birmingham, Alabama1 trial

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

University Of Alabama

Phase 2

Los Angeles, California1 trial

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

UCLA

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.